XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation
6 Months Ended
Jul. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Share-Based Compensation

9.  Share-Based Compensation

The Company accounts for share-based compensation under the provisions of ASC 718, Compensation - Stock Compensation (“ASC 718”), which requires the Company to measure and recognize compensation expense for all share-based payments at fair value.

Total share-based compensation expense included in the Consolidated Statements of Operations for the 13 and 26 weeks ended July 31, 2021 was $9.0 million ($6.8 million, net of tax) and $21.6 million ($16.4 million, net of tax), respectively, and for the 13 and 26 weeks ended August 1, 2020 was $11.6 million ($7.0 million, net of tax) and $15.7 million ($9.5 million, net of tax), respectively.    

Stock Option Grants

The Company has granted time-based stock option awards.  Time-based stock option awards vest over the requisite service period of the award or to an employee’s eligible retirement eligible date, if earlier. A summary of the Company’s stock option activity for the 26 weeks ended July 31, 2021 follows:

 

 

 

 

 

 

 

Weighted-

Average

 

 

Weighted-

Average

Remaining

Contractual

 

 

Aggregate

 

 

 

Options

 

 

Exercise Price

 

 

Term

 

 

Intrinsic Value

 

 

 

(In thousands)

 

 

 

 

 

 

(In years)

 

 

(In thousands)

 

Outstanding - January 30, 2021

 

 

3,940

 

 

$

14.87

 

 

 

 

 

 

 

 

 

Granted

 

 

449

 

 

$

32.58

 

 

 

 

 

 

 

 

 

Exercised (1)

 

 

(771

)

 

$

16.33

 

 

 

 

 

 

 

 

 

Outstanding - July 31, 2021

 

 

3,618

 

 

$

16.76

 

 

 

4.9

 

 

$

64,071

 

Vested and expected to vest - July 31, 2021

 

 

2,778

 

 

$

16.50

 

 

 

3.5

 

 

$

28,599

 

Exercisable - July 31, 2021 (2)

 

 

1,788

 

 

$

16.28

 

 

 

2.0

 

 

$

32,531

 

 

(1)

Options exercised during the 26 weeks ended July 31, 2021 ranged in price from $8.62 to $21.41.

(2)

Options exercisable represent “in-the-money” vested options based upon the weighted-average exercise price of vested options compared to the Company’s stock price on July 31, 2021.

Cash received from the exercise of stock options was $13.1 million for the 26 weeks ended July 31, 2021. The actual tax benefit realized from share-based payments totaled $4.1 million for the 26 weeks ended July 31, 2021. There were no stock options exercised during the 26 weeks ended August 1, 2020.

As of July 31, 2021, there was $8.6 million of unrecognized compensation expense for stock option awards that is expected to be recognized over a weighted average period of 2.2 years.  

The fair value of stock options was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:

 

 

 

26 Weeks Ended

 

26 Weeks Ended

 

 

July 31,

 

August 1,

Black-Scholes Option Valuation Assumptions

 

2021

 

2020

Risk-free interest rate (1)

 

0.9%

 

0.3 - 0.6%

Dividend yield

 

1.6%

 

3.5 - 6.0%

Volatility factor (2)

 

50.7%

 

43.1 - 48.7%

Weighted-average expected term (3)

 

4.5 years

 

4.4 years

 

(1)

Based on the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected life of our stock options.

(2)

Based on historical volatility of the Company’s common stock.

(3)

Represents the period of time that options are expected to be outstanding. The weighted average expected option terms were determined based on historical experience.            

Restricted Stock Grants

Time-based restricted stock awards are comprised of time-based restricted stock units.  These awards vest over three years.  Time-based restricted stock units receive dividend equivalents in the form of additional time-based restricted stock units, which are subject to the same restrictions and forfeiture provisions as the original award.

Performance-based restricted stock awards include performance-based restricted stock units.  These awards cliff vest at the end of a three-year period based upon the Company’s achievement of pre-established goals throughout the term of the award.  Performance-based restricted stock units receive dividend equivalents in the form of additional performance-based restricted stock units, which are subject to the same restrictions and forfeiture provisions as the original award.

The grant date fair value of time-based restricted stock awards is based on the closing market price of the Company’s common stock on the date of grant. A Monte-Carlo simulation was utilized to determine the fair value for performance-based restricted stock awards.

A summary of the Company’s restricted stock activity is presented in the following tables:

 

 

 

Time-Based Restricted

Stock Units

 

 

Performance-Based Restricted

Stock Units

 

 

 

July 31, 2021

 

 

July 31, 2021

 

(Shares in thousands)

 

Shares

 

 

Weighted-

Average

Grant Date

Fair Value

 

 

Shares

 

 

Weighted-

Average

Grant Date

Fair Value

 

Nonvested - January 30, 2021

 

 

3,698

 

 

$

12.42

 

 

 

1,868

 

 

$

17.44

 

Granted

 

 

657

 

 

$

32.64

 

 

 

320

 

 

$

39.93

 

Vested

 

 

(1,268

)

 

$

13.45

 

 

 

(275

)

 

$

19.48

 

Cancelled

 

 

(163

)

 

$

12.68

 

 

 

(308

)

 

$

16.88

 

Nonvested - July 31, 2021

 

 

2,924

 

 

$

16.30

 

 

 

1,605

 

 

$

23.67

 

 

As of July 31, 2021, there was $36.0 million of unrecognized compensation expense related to non-vested, time-based restricted stock unit awards that is expected to be recognized over a weighted-average period of 2.2 years. Based on current probable performance, there is $10.9 million of unrecognized compensation expense related to performance-based restricted stock unit awards which will be recognized as achievement of performance goals is probable over a one- to three- year period.

As of July 31, 2021, the Company had 7.6 million shares available for all equity grants.